Neurimmune AG

Neurimmune AG is a leading biopharmaceutical company focused on translating human immune memory into innovative antibody therapeutics. With a commitment to addressing critical healthcare needs, Neurimmune AG leverages its proprietary Reverse Translational Medicine technology platform to transform genetic information from human white blood cells into highly selective and high-affinity antibody drug candidates.

Neurimmune AG is dedicated to developing groundbreaking treatments for a range of debilitating diseases. The company’s robust pipeline includes promising drug candidates targeting Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), fronto-temporal dementia, cardiomyopathy, and type 2 diabetes. Neurimmune AG's approach aims to provide transformative therapeutic solutions for patients worldwide.

Located at Wagistrasse 18, Zurich Schlieren, Zurich 8952, CH, Neurimmune AG is poised for continued growth and innovation in the pharmaceutical industry. We invite the management team at Neurimmune AG to create a customized and exclusive company showcase and product listing on our platform, further amplifying their reach and impact.